A risk prediction model consisting of 8 independent diagnostics can provide potential insight into a patient’s risk for Barrett’s esophagus before endoscopy, according to a study in published in Lancet Digital Health.
The U.S. Food and Drug Administration is adding to a list of recalled lots of popular heartburn medications — including generic forms of Zantac — because the pills might contain small amounts of the suspected carcinogen N-nitrosodimethylamine.
Mylan has announced a recall of 3 lots of Nizatidine Capsules as the products were manufactured with an active pharmaceutical ingredient (API) that contained trace amounts of N-nitrosodimethylamine (NDMA), a probable human carcinogen.
Patients with female eosinophilic esophagitis considering pregnancy should be informed that to date, no increased maternal and fetal risk was observed in pregnant patients with EoE on and off EoE-specific medication.
The acetic acid method of biopsy (Portsmouth protocol) was shown to be feasible in Barrett’s surveillance, with clinician and patient acceptance; moreover, the reduced number of biopsies with this technique indicate that acetic acid biopsies could produce cost savings.
Most infants and school-aged children with EA off medication have a normal [reflux index], yet experience a significant number of nonacid RBM. After manual revision of the tracings, a high percentage of RBM was deleted.
The ﬁndings indicate that reﬂux plays a role in the pathogenesis of EoE, more relevant in PPI-responsive cases, and that PPIs mainly act by antireﬂux mechanisms, supporting long-term prescription in PPI-responsive EoE.
Compared with proton pump inhibitor (PPI) therapy, magnetic sphincter augmentation (MSA) was far superior for reducing regurgitation in regurgitative gastroesophageal reflux disease (GERD), and relief is sustained over 12 months.
In most cases of diagnostic esophagogastroduodenoscopy (EGD) performed for refractory gastro-esophageal reflux disease (GERD), symptoms alone did not result in pathological findings that prompted a change in the patient’s GERD management.
Eosinophilic esophagitis (EoE) is a clinicopathologic disease for which proton pump inhibitors (PPIs) are now considered a treatment option. Of children with EoE, 32% responded to high-dose proton pump inhibitor (HDPPI) therapy.
EoE activity rapidly recurred after initial response to oral viscous budesonide (OVB) or fluticasone from a multidose inhaler (MDI), indicating the need for maintenance therapy for patients who achieve histologic response to topical steroids.